The emerging role of Artificial Intelligence in proton therapy: A review.

Journal: Critical reviews in oncology/hematology
Published Date: Sep 2, 2024

Abstract

Artificial intelligence (AI) has made a tremendous impact in the space of healthcare, and proton therapy is not an exception. Proton therapy has witnessed growing popularity in oncology over recent decades, and researchers are increasingly looking to develop AI and machine learning tools to aid in various steps of the treatment planning and delivery processes. This review delves into the emergent role of AI in proton therapy, evaluating its development, advantages, intended clinical contexts, and areas of application. Through the analysis of 76 studies, we aim to underscore the importance of AI applications in advancing proton therapy and to highlight their prospective influence on clinical practices.

Authors

  • Lars Johannes Isaksson
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Federico Mastroleo
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Maria Giulia Vincini
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. mariagiulia.vincini@ieo.it.
  • Giulia Marvaso
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Mattia Zaffaroni
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. mattia.zaffaroni@ieo.it.
  • Michał Gola
    Department of Human Histology and Embryology, Collegium Medicum, School of Medicine, University of Warmia and Mazury, Olsztyn 10-082, Poland.
  • Giovanni Carlo Mazzola
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Luca Bergamaschi
    Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Simona Gaito
    Proton Clinical Outcomes Unit, The Christie NHS Proton Beam Therapy Centre, Manchester M20 4BX, UK; Division of Clinical Cancer Science, School of Medical Sciences, The University of Manchester Manchester M13 9PL, UK.
  • Filippo Alongi
    Radiation Oncology Department, Sacro Cuore Don Calabria Hospital, Via Don A.Sempreboni 5, 37024, Negrar-Verona, Italy.
  • Jerome Doyen
    Centre Antoine-Lacassagne, University of Côte d'Azur, Nice 06189, France; University Côte d'Azur, CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, Institute for Research on Cancer and Aging of Nice (IRCAN), 06189 Nice, France, Centre Antoine Lacassagne, Nice 06189, France.
  • Piero Fossati
    EBG MedAustron GmbH, Marie-Curie-Str. 5, Wiener Neustadt 2700, Austria; Department of General and Translational Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, 3500, Austria.
  • Karin Haustermans
    KU Leuven - Department of Oncology - Laboratory of Experimental Radiotherapy, Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, 3000 Leuven, Belgium.
  • Morten Høyer
    Aarhus University (AU), Nordre Ringgade 1, Aarhus C 8000, Denmark.
  • Johannes Albertus Langendijk
    Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Raùl Matute
    Centro de Protonterapia Quironsalud, Pozuelo de Alarcón, Madrid 28223, Spain.
  • Ester Orlandi
    Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Marco Schwarz
    Proton therapy Department, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy.
  • Esther G C Troost
    OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.
  • Vladimir Vondracek
    Proton Therapy Centre Czech, Prague, Czech Republic and Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czech Republic.
  • Davide La Torre
    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Giuseppe Curigliano
    Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.
  • Giuseppe Petralia
    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Roberto Orecchia
    Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Daniela Alterio
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy.
  • Barbara Alicja Jereczek-Fossa
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.

Keywords

External Resources

Popular Topics
Recent Journals